JW Pharmaceutical Overview
- Year Founded
-
1945
- Status
-
Public
- Employees
-
1,102
- Stock Symbol
-
001060
- Investments
-
4
- Share Price
-
$15.59
- (As of Wednesday Closing)
JW Pharmaceutical General Information
Description
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
Contact Information
Website
www.jw-pharma.co.krCorporate Office
- JW Gwacheon Tower, 38, Gwacheon-daero 7-gil
- Gwacheon-si, Gyeonggi-do 13840
- South Korea
Corporate Office
- JW Gwacheon Tower, 38, Gwacheon-daero 7-gil
- Gwacheon-si, Gyeonggi-do 13840
- South Korea
JW Pharmaceutical Stock Performance
As of 21-May-2025, JW Pharmaceutical’s stock price is $15.59. Its current market cap is $364M with 23M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.59 | $15.25 | $13.17 - $25.38 | $364M | 23M | 60.7K | $1.94 |
JW Pharmaceutical Financials Summary
As of 31-Dec-2024, JW Pharmaceutical has a trailing 12-month revenue of $527M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 425,986 | 425,986 | 744,645 | 380,674 |
| Revenue | 527,233 | 527,233 | 572,509 | 529,635 |
| EBITDA | 78,190 | 78,190 | 64,308 | 51,283 |
| Net Income | 47,668 | 47,668 | 28,304 | 24,682 |
| Total Assets | 410,462 | 410,462 | 500,542 | 497,243 |
| Total Debt | 62,273 | 62,273 | 132,136 | 165,920 |
JW Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
JW Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
JW Pharmaceutical Patents
JW Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023352113-A1 | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine mono succinate | Pending | 30-Sep-2022 | ||
| AU-2023352114-A1 | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine | Pending | 29-Sep-2022 | ||
| AU-2023348200-A1 | A process for the manufacture of salts and crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine and novel crystalline forms | Pending | 29-Sep-2022 | ||
| AU-2022299278-A1 | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hemisuccinate | Pending | 22-Jun-2021 | ||
| US-20240300949-A1 | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hemisuccinate | Pending | 22-Jun-2021 | C07D471/14 |
JW Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
JW Pharmaceutical Investments & Acquisitions (4)
JW Pharmaceutical’s most recent deal was a Early Stage VC with S&E bio for . The deal was made on 17-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| S&E bio | 17-Nov-2022 | Early Stage VC | Drug Discovery | ||
| JW Euvipharm | 04-Sep-2020 | Merger/Acquisition | Pharmaceuticals | ||
| S&E bio | 11-May-2020 | Early Stage VC | Drug Discovery | ||
| Argonaut Therapeutics | 19-Sep-2018 | Early Stage VC | Drug Discovery |
JW Pharmaceutical ESG
Risk Overview
Risk Rating
Updated April, 26, 2025
37.83 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
JW Pharmaceutical Exits (1)
JW Pharmaceutical’s most recent exit was on 19-Sep-2018 from Argonaut Therapeutics. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Argonaut Therapeutics | 19-Sep-2018 | Completed |
|
JW Pharmaceutical Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| JW Euvipharm | Duc Hoa District, Vietnam | 2005 |
JW Pharmaceutical FAQs
-
When was JW Pharmaceutical founded?
JW Pharmaceutical was founded in 1945.
-
Where is JW Pharmaceutical headquartered?
JW Pharmaceutical is headquartered in Gwacheon-si, South Korea.
-
What is the size of JW Pharmaceutical?
JW Pharmaceutical has 1,102 total employees.
-
What industry is JW Pharmaceutical in?
JW Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is JW Pharmaceutical a private or public company?
JW Pharmaceutical is a Public company.
-
What is JW Pharmaceutical’s stock symbol?
The ticker symbol for JW Pharmaceutical is 001060.
-
What is the current stock price of JW Pharmaceutical?
As of 21-May-2025 the stock price of JW Pharmaceutical is $15.59.
-
What is the current market cap of JW Pharmaceutical?
The current market capitalization of JW Pharmaceutical is $364M.
-
What is JW Pharmaceutical’s current revenue?
The trailing twelve month revenue for JW Pharmaceutical is $527M.
-
What is JW Pharmaceutical’s annual earnings per share (EPS)?
JW Pharmaceutical’s EPS for 12 months was $1.94.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
